{"id":"dabigatran-etexilate-pradaxa","safety":{"commonSideEffects":[{"rate":"2-5","effect":"Bleeding (major and minor)"},{"rate":"10-15","effect":"Dyspepsia/gastrointestinal discomfort"},{"rate":"5-10","effect":"Gastritis"},{"rate":"5-8","effect":"Abdominal pain"},{"rate":"3-5","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dabigatran etexilate is rapidly converted by esterase enzymes in the blood to its active form, dabigatran. Dabigatran directly inhibits thrombin (Factor IIa), a key serine protease responsible for converting fibrinogen to fibrin and amplifying the coagulation cascade. By blocking thrombin activity, it prevents clot formation without requiring antithrombin III as a cofactor, unlike warfarin and heparin-based anticoagulants.","oneSentence":"Dabigatran etexilate is a prodrug that converts to dabigatran, a direct thrombin inhibitor that blocks the final step of the coagulation cascade.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:32:01.945Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke and systemic embolism prevention"},{"name":"Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE)"},{"name":"Prophylaxis of DVT and PE following hip replacement surgery"}]},"trialDetails":[{"nctId":"NCT03568890","phase":"PHASE4","title":"Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","startDate":"2018-09-01","conditions":"Left Atrial Appendage Closure, Thrombosis, Stroke","enrollment":510},{"nctId":"NCT07497893","phase":"NA","title":"FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants)","status":"NOT_YET_RECRUITING","sponsor":"Ewha Womans University Mokdong Hospital","startDate":"2026-12-01","conditions":"Atrial Fibrillation (AF), Upper Gastrointestinal Bleeding (UGIB), Gastrointestinal Hemorrhage (Clinically Important, Upper)","enrollment":1000},{"nctId":"NCT05387954","phase":"PHASE3","title":"PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-07-07","conditions":"Cryptogenic Ischemic Stroke, Patent Foramen Ovale","enrollment":792},{"nctId":"NCT06650501","phase":"PHASE4","title":"Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2026-01-15","conditions":"Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia","enrollment":300},{"nctId":"NCT04618913","phase":"","title":"Anticoagulation in Patients With Venous Thromboembolism and Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-12-14","conditions":"Neoplasms, Embolism","enrollment":1},{"nctId":"NCT05038228","phase":"","title":"High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-08-01","conditions":"Atrial Fibrillation","enrollment":1},{"nctId":"NCT04809818","phase":"PHASE1","title":"A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects","status":"COMPLETED","sponsor":"Lumosa Therapeutics Co., Ltd.","startDate":"2021-03-21","conditions":"Acute Ischemic Stroke","enrollment":65},{"nctId":"NCT07242326","phase":"","title":"SNAP AF-52: Dose Appropriateness and Adherence to Oral Anticoagulation in Adults ≥65 With Atrial Fibrillation in Primary Care (Ordu, Türkiye)","status":"ENROLLING_BY_INVITATION","sponsor":"Kotyora Family Medicine Health Management and Education Association","startDate":"2025-12-15","conditions":"Medication Adherence, Atrial Fibrillation (AF), Direct Oral Anticoagulants (DOACs)","enrollment":1000},{"nctId":"NCT04611893","phase":"","title":"Monitoring of NOAC Therapy: Standardizing Reference Intervals","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2020-11-05","conditions":"Ischemic Stroke, Stroke, Acute, Stroke Syndrome","enrollment":308},{"nctId":"NCT05825573","phase":"PHASE3","title":"Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2023-05-15","conditions":"Intracardiac Thrombus, STEMI, Heart Failure","enrollment":340},{"nctId":"NCT03947385","phase":"PHASE1, PHASE2","title":"Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions","status":"RECRUITING","sponsor":"IDEAYA Biosciences","startDate":"2019-06-28","conditions":"Metastatic Uveal Melanoma, Cutaneous Melanoma, Colorectal Cancer","enrollment":336},{"nctId":"NCT07358416","phase":"","title":"Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Petrovsky National Research Centre of Surgery","startDate":"2025-05-01","conditions":"Thrombosis, Bleeding, Cerebral Hypoxia During and/or Resulting From A Procedure","enrollment":500},{"nctId":"NCT04045665","phase":"PHASE3","title":"Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2019-12-13","conditions":"Atrial Fibrillation, Stroke, Bleeding","enrollment":3200},{"nctId":"NCT07352358","phase":"PHASE4","title":"Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2026-01-30","conditions":"Cerebral Venous Thrombosis","enrollment":72},{"nctId":"NCT03968393","phase":"PHASE4","title":"Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2019-06-14","conditions":"Stroke, Atrial Fibrillation","enrollment":2270},{"nctId":"NCT06504862","phase":"PHASE1","title":"A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2024-08-20","conditions":"Healthy","enrollment":32},{"nctId":"NCT05838664","phase":"","title":"A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-07-07","conditions":"Atrial Fibrillation","enrollment":2140403},{"nctId":"NCT04045093","phase":"PHASE4","title":"Dabigatran for Mitral Stenosis Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2020-10-22","conditions":"Atrial Fibrillation, Mitral Stenosis","enrollment":370},{"nctId":"NCT03463317","phase":"PHASE4","title":"Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2018-02-28","conditions":"Atrial Fibrillation","enrollment":912},{"nctId":"NCT07190430","phase":"PHASE1","title":"A Study to Learn If the Study Medicine Called PF-08049820 Changes How the Body Processes the Other Study Medicines Called Oral Contraceptives, Midazolam, and Dabigatran in Healthy Adult Female Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2025-10-03","conditions":"Atopic Dermatitis","enrollment":16},{"nctId":"NCT04684212","phase":"NA","title":"Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF","status":"WITHDRAWN","sponsor":"Brian O'Neill MD","startDate":"2024-06-01","conditions":"Atrial Fibrillation, Left Atrial Appendage Thrombosis, CVA","enrollment":""},{"nctId":"NCT04284839","phase":"PHASE3","title":"The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2021-07-18","conditions":"Bleeding Post Cardiac Surgery, Indication for Anticoagulation","enrollment":3500},{"nctId":"NCT06581965","phase":"PHASE4","title":"inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2024-11-11","conditions":"Venous Thromboembolism, Venous Thromboses, Pulmonary Embolism","enrollment":10078},{"nctId":"NCT06945276","phase":"PHASE1","title":"Phase 1 Study on Bioavailability, Food Effect, and Drug-Drug Interaction of ALG-097558 Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-05-13","conditions":"COVID-19","enrollment":51},{"nctId":"NCT06791187","phase":"PHASE1","title":"A Study in Healthy People to Test Whether BI 1291583 Influences the Amount of Dabigatran in the Body","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2025-01-23","conditions":"Healthy","enrollment":14},{"nctId":"NCT07083609","phase":"","title":"Treatment Outcomes of Direct Oral Anticoagulants in Cerebral Venous Thrombosis in Vietnam","status":"RECRUITING","sponsor":"Hieu Trung Dinh","startDate":"2025-07-11","conditions":"Cerebral Venous Thrombosis","enrollment":69},{"nctId":"NCT05990894","phase":"","title":"Steroid for Treatment of Acute/Subacute Severe Cerebral Venous Thrombosis.","status":"COMPLETED","sponsor":"Xuanwu Hospital, Beijing","startDate":"2020-07-01","conditions":"Cerebral Venous Thrombosis","enrollment":170},{"nctId":"NCT03778502","phase":"","title":"DOAC in Unusual Site Venous Thrombosis","status":"COMPLETED","sponsor":"University of Malta","startDate":"2019-10-01","conditions":"Splanchnic Vein Thrombosis, Cerebral Vein Thrombosis, Ovarian Vein Thrombosis","enrollment":358},{"nctId":"NCT06876623","phase":"PHASE1","title":"Bioequivalence Study of Two Dabigatran Etexilate Mesylate Capsules in Healthy Subjects","status":"COMPLETED","sponsor":"The Affiliated Hospital Of Guizhou Medical University","startDate":"2019-12-10","conditions":"Bioequivalence of Dabigatran Etexilate Mesylate Capsules From Two Different Manufacturers in Healthy Chinese Subjects","enrollment":88},{"nctId":"NCT03087487","phase":"","title":"Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-06-01","conditions":"Non-Valvular Atrial Fibrillation","enrollment":466991},{"nctId":"NCT06101667","phase":"NA","title":"Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2023-10-15","conditions":"Acute Ischemic Stroke, Basilar Artery Occlusion","enrollment":224},{"nctId":"NCT03539055","phase":"PHASE4","title":"Efficacy of Short Term Dabigatran Etexilate Followed by Aspirin Monotherapy After LAA (Left Atrial Appendage) Device Closure (the DEA-LAA Study).","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2018-09-01","conditions":"Atrial Fibrillation, Device Related Thrombus, Left Atrial Appendage Thrombosis","enrollment":100},{"nctId":"NCT07011095","phase":"EARLY_PHASE1","title":"DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial","status":"NOT_YET_RECRUITING","sponsor":"Population Health Research Institute","startDate":"2025-09-03","conditions":"Atrial Fibrillation (AF), Stroke (in Patients With Atrial Fibrillation)","enrollment":100},{"nctId":"NCT06983795","phase":"","title":"Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study","status":"NOT_YET_RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-07","conditions":"Ischemic Stroke, Patent Foramen Ovale","enrollment":1000},{"nctId":"NCT03129490","phase":"PHASE4","title":"The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Herlev and Gentofte Hospital","startDate":"2023-04-01","conditions":"Atrial Fibrillation, Atrial Flutter","enrollment":11000},{"nctId":"NCT04700826","phase":"PHASE4","title":"Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2021-06-01","conditions":"Atrial Fibrillation","enrollment":3000},{"nctId":"NCT04532528","phase":"","title":"ReAHEAD: A Study to Find Out Whether Education Improves Adherence to Dabigatran in People With Atrial Fibrillation Who Are Younger Than 75 Years","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-08-27","conditions":"Atrial Fibrillation","enrollment":897},{"nctId":"NCT03129555","phase":"PHASE4","title":"The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Herlev and Gentofte Hospital","startDate":"2023-04-01","conditions":"Deep Vein Thrombosis, Pulmonary Embolism","enrollment":5000},{"nctId":"NCT06957366","phase":"NA","title":"Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure","status":"RECRUITING","sponsor":"McMaster University","startDate":"2025-04-01","conditions":"Atrial Fibrillation (AF), VTE","enrollment":920},{"nctId":"NCT05735639","phase":"PHASE4","title":"THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)","status":"RECRUITING","sponsor":"Imperial College London","startDate":"2024-01-22","conditions":"Venous Thromboembolism, Varicose Veins","enrollment":6660},{"nctId":"NCT04394234","phase":"","title":"A Study of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-05-15","conditions":"Uterine Hemorrhage","enrollment":961985},{"nctId":"NCT06533280","phase":"PHASE1","title":"VH3739937 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers Including Relative Bioavailability (RBA), Optional Food Effect (FE), and Drug-drug Interaction (DDI)","status":"WITHDRAWN","sponsor":"ViiV Healthcare","startDate":"2024-08-02","conditions":"HIV Infections","enrollment":""},{"nctId":"NCT03752294","phase":"PHASE1","title":"A Novel Therapeutic Target for Alzheimer's Disease in Men and Women 50-85 Years of Age.","status":"WITHDRAWN","sponsor":"University of Rhode Island","startDate":"2019-05","conditions":"Mild Cognitive Impairment, Mild Alzheimer's Disease","enrollment":""},{"nctId":"NCT06449469","phase":"NA","title":"The Nordic Aortic Valve Intervention Trial 4 (NOTION-4)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Rigshospitalet, Denmark","startDate":"2021-05-01","conditions":"Aortic Valve Stenosis, Cardiovascular Diseases, Heart Diseases","enrollment":352},{"nctId":"NCT06322953","phase":"PHASE3","title":"Timing to Restart Direct Oral Anticoagulants After Traumatic Intracranial Haemorrhage","status":"RECRUITING","sponsor":"Walton Centre NHS Foundation Trust","startDate":"2025-03-10","conditions":"Traumatic Intracranial Haemorrhage","enrollment":1084},{"nctId":"NCT03504007","phase":"","title":"Registry of Patients Prescribed Anticoagulation","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2013-03-01","conditions":"Acute Deep Vein Thrombosis, Acute Pulmonary Embolism","enrollment":10000},{"nctId":"NCT06571149","phase":"PHASE4","title":"Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2025-03-14","conditions":"Ischemic Stroke","enrollment":906},{"nctId":"NCT05959447","phase":"PHASE1","title":"Evaluation of the Potential Drug-drug Interactions Between Gemfibrozil or Dabigatran Etexilate and Camlipixant","status":"COMPLETED","sponsor":"Bellus Health Inc. - a GSK company","startDate":"2023-07-26","conditions":"Cough, Healthy","enrollment":45},{"nctId":"NCT06887270","phase":"NA","title":"Peri-procedural Management of Direct Oral Anticoagulants for Central VENOus Catheters in CAncer Patients With Venous Thromboembolism or Atrial Fibrillation Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"University Health Network, Toronto","startDate":"2025-09","conditions":"Anticoagulant-induced Bleeding, Direct Oral Anticoagulant, Cancer","enrollment":10},{"nctId":"NCT04099732","phase":"PHASE1","title":"A Study in Healthy Men to Test the Influence of BI 1358894 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2019-10-07","conditions":"Healthy","enrollment":26},{"nctId":"NCT05750680","phase":"","title":"DOCE Study Interaction Between Direct Oral Anticoagulants and Drug-metabolizing Enzyme Inducers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-05-13","conditions":"Atrial Fibrillation, Thromboembolism, Venous","enrollment":23},{"nctId":"NCT03343704","phase":"PHASE3","title":"This Study Looks at the Effects of Idarucizumab in Patients Who Take Dabigatran and Need Emergency Surgery or Are Bleeding","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2018-03-26","conditions":"Hemorrhage","enrollment":19},{"nctId":"NCT05068414","phase":"","title":"Assessment of the Incidence of Hemorrhagic and Ischemic Events in Post-angioplasty in Anticoagulated Coronary Patients with Atrial Fibrillation","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2021-04-12","conditions":"Atrial Fibrillation, Acute Coronary Syndrome, Thrombosis","enrollment":122},{"nctId":"NCT00844415","phase":"PHASE2","title":"Safety and Tolerability of Dabigatran Etexilate in Adolescents","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-06-01","conditions":"Venous Thromboembolism","enrollment":9},{"nctId":"NCT00967447","phase":"","title":"Study to Evaluate the Safety and Efficacy of Pradaxar for the Prevention of Venous Thromboembolism in the Mexican Population Undergoing Elective Total Hip or Knee Replacement Surgery","status":"TERMINATED","sponsor":"Boehringer Ingelheim","startDate":"2009-02-01","conditions":"Thromboembolism, Arthroplasty, Replacement, Hip","enrollment":2},{"nctId":"NCT06818279","phase":"PHASE2, PHASE3","title":"Compare the Efficacy and Safety of Dabigatran and Enoxaparin in Patients With Portal Vein Thrombosis With Cirrhosis","status":"NOT_YET_RECRUITING","sponsor":"Institute of Liver and Biliary Sciences, India","startDate":"2025-01-31","conditions":"Portal Vein Thrombosis, Liver Cirrhosis","enrollment":120},{"nctId":"NCT04234698","phase":"","title":"Patient Characteristics, Treatment Patterns And Incidence Of Events (Discontinuation, Persistence, Key Primary Clinical Outcomes) In NVAF Patients Initiating OAC Therapy In Colombia","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-03-22","conditions":"Atrial Fibrillation","enrollment":2076},{"nctId":"NCT02945020","phase":"PHASE1","title":"A Pharmacokinetic Interaction Study Between Odalasvir, Given as a Single Agent or in Combination With Simeprevir, and Dabigatran Etexilate Mesylate in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2016-11-10","conditions":"Healthy","enrollment":15},{"nctId":"NCT04208061","phase":"PHASE1","title":"A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2019-12-18","conditions":"Healthy","enrollment":28},{"nctId":"NCT05378035","phase":"","title":"DOAC in Chinese Patients With Atrial Fibrillation","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2022-09-28","conditions":"Atrial Fibrillation, Stroke, Stroke, Acute","enrollment":427},{"nctId":"NCT06693518","phase":"PHASE1","title":"A Study to Learn About if the Study Medicine Called Ibuzatrelvir Changes How the Body Process the Other Medicine Dabigatran Etexilate in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-11-22","conditions":"SARS-CoV-2 Infections","enrollment":20},{"nctId":"NCT03996772","phase":"PHASE3","title":"PREvention of STroke in Intracerebral haemorrhaGE Survivors With Atrial Fibrillation","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2019-06-03","conditions":"Atrial Fibrillation, Intracerebral Hemorrhage","enrollment":319},{"nctId":"NCT05492318","phase":"PHASE1","title":"Perpetrator DDI Potential of Givinostat as Inhibitor and Inducer of CYP3A and P-gp Activity","status":"COMPLETED","sponsor":"Italfarmaco","startDate":"2022-03-21","conditions":"Drug-Drug Interaction, Heathy Volunteer","enrollment":26},{"nctId":"NCT03062319","phase":"PHASE4","title":"Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis","status":"TERMINATED","sponsor":"National Hospital Organization Osaka National Hospital","startDate":"2017-04-06","conditions":"Ischemic Stroke, Atrial Fibrillation, Atherothrombosis","enrollment":321},{"nctId":"NCT04062097","phase":"","title":"Registration of Idarucizumab for Patients with IntraCranial Hemorrhage","status":"COMPLETED","sponsor":"University Hospital, Essen","startDate":"2019-09-19","conditions":"Intracranial Hemorrhage","enrollment":104},{"nctId":"NCT01924065","phase":"PHASE3","title":"Risk of Stroke and Silent Cerebrovascular Thromboembolism After Cardioversion of Atrial Fibrillation","status":"COMPLETED","sponsor":"Suleyman Demirel University","startDate":"2013-08","conditions":"Atrial Fibrillation, Cardioversion, Cerebrovascular Stroke","enrollment":112},{"nctId":"NCT05788328","phase":"PHASE1","title":"A Drug-Drug Interaction Study to Estimate the Effect of PF-07081532 on the Pharmacokinetics of Dabigatran and Rosuvastatin in Overweight or Obese Adult Participants","status":"TERMINATED","sponsor":"Pfizer","startDate":"2023-03-27","conditions":"Healthy","enrollment":16},{"nctId":"NCT04979780","phase":"","title":"Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-07-20","conditions":"Treatment of Venous Thromboembolism in Cancer Patients, Prophylaxis of Recurrent Venous Thromboembolism in Cancer Patients","enrollment":3708},{"nctId":"NCT06615596","phase":"EARLY_PHASE1","title":"Discontinuation of Anticoagulations After Successful Catheter Ablation of Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2025-01","conditions":"Atrial Fibrillation (AF)","enrollment":3160},{"nctId":"NCT03596502","phase":"","title":"Direct Oral Anticoagulants in Patients with Atrial Fibrillation (DOACs Vs Warfarin)","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2018-02-01","conditions":"Atrial Fibrillation, Ischemic Stroke, Systemic Embolization","enrollment":402764},{"nctId":"NCT04477837","phase":"","title":"Prospective Comparison of Incidence of Heavy Menstrual Bleeding in Women Treated With Direct Oral Anticoagulants","status":"COMPLETED","sponsor":"Cardioangiologisches Centrum Bethanien","startDate":"2020-10-15","conditions":"Heavy Menstrual Bleeding","enrollment":84},{"nctId":"NCT06556446","phase":"","title":"Intravenous Thrombolysis in Patients With Ischemic Stroke and Recent Ingestion of Direct Oral Anticoagulants","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2024-01-01","conditions":"Ischemic Stroke","enrollment":2800},{"nctId":"NCT05673889","phase":"PHASE1","title":"A Study to Understand the Effect of a Study Medicine Called ARV-471 on Dabigatran Etexilate in Healthy Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-01-27","conditions":"Healthy","enrollment":24},{"nctId":"NCT06551402","phase":"PHASE3","title":"Dabigatran Versus Rivaroxaban in Cerebral Venous Thrombosis","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2024-08-09","conditions":"Cerebral Venous Sinus Thrombosis","enrollment":200},{"nctId":"NCT06551415","phase":"PHASE3","title":"Dabigatran Versus Apixaban in Cerebral Venous Thrombosis","status":"RECRUITING","sponsor":"Kafrelsheikh University","startDate":"2021-08-01","conditions":"Cerebral Venous Sinus Thrombosis","enrollment":200},{"nctId":"NCT04249401","phase":"","title":"Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem)","status":"COMPLETED","sponsor":"Bayer","startDate":"2020-03-01","conditions":"Atrial Fibrillation","enrollment":134897},{"nctId":"NCT06329895","phase":"PHASE1","title":"A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-03-25","conditions":"Advanced Non-small Cell Lung Cancer, EGFR Mutation, HER2 Mutation","enrollment":15},{"nctId":"NCT06486792","phase":"PHASE4","title":"Stroke Prevention In Ischemic Stroke With Covert Atrial Fibrillation","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2024-09-01","conditions":"Stroke, Ischemic Stroke, Cerebral Infarction","enrollment":1148},{"nctId":"NCT05536791","phase":"","title":"A Study in Europe Based on Medical Records That Looks at the Safety of Dabigatran in Children Below 2 Years of Age Who Have Had a Blood Clot and Are at Risk of Developing Another Blood Clot","status":"WITHDRAWN","sponsor":"Boehringer Ingelheim","startDate":"2022-11-24","conditions":"Venous Thromboembolism","enrollment":""},{"nctId":"NCT04847752","phase":"","title":"Study of Predictive Factors Related to Prognosis of Patients With Ischemic Stroke Due to Large-artery Atherosclerosis","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2021-03-01","conditions":"Ischemic Stroke, Large-Artery Atherosclerosis (Embolus/Thrombosis)","enrollment":1000},{"nctId":"NCT06441916","phase":"PHASE1","title":"Bioequivalence Study of Dabigatran Etexilate Capsules 150 mg in Healthy Thai Volunteers Under Fasting Conditions","status":"NOT_YET_RECRUITING","sponsor":"International Bio service","startDate":"2024-09-25","conditions":"Healthy Volunteer, Dabigatran, Bioequivalence Study","enrollment":60},{"nctId":"NCT05472766","phase":"NA","title":"Anticoagulation Therapy Timing in Atrial Fibrillation After Acute and Chronic Subdural Hematoma","status":"TERMINATED","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2022-11-24","conditions":"Subdural Hematoma, Atrial Fibrillation","enrollment":1},{"nctId":"NCT04437303","phase":"PHASE4","title":"Periprocedural Continuation Versus Interruption of Oral Anticoagulant Drugs During Transcatheter Aortic Valve Implantation (POPular PAUSE TAVI)","status":"COMPLETED","sponsor":"St. Antonius Hospital","startDate":"2020-11-25","conditions":"Aortic Valve Disease, Aortic Valve Stenosis, Stroke","enrollment":858},{"nctId":"NCT04782076","phase":"PHASE1","title":"A Drug Drug Interaction (DDI) Study of Selpercatinib and Dabigatran in Healthy Participants","status":"COMPLETED","sponsor":"Loxo Oncology, Inc.","startDate":"2021-03-05","conditions":"Healthy","enrollment":36},{"nctId":"NCT06401616","phase":"PHASE4","title":"Can Patients With Atrial Fibrillation Safely Discontinue Anticoagulant Therapy After Cardiac Surgery? (ATLAAC)","status":"RECRUITING","sponsor":"Odense University Hospital","startDate":"2024-05-21","conditions":"Atrial Fibrillation, Left Atrial Appendage Absent, Anticoagulant Adverse Reaction","enrollment":1220},{"nctId":"NCT03759938","phase":"NA","title":"OPTIMAS: OPtimal TIMing of Anticoagulation After Acute Ischaemic Stroke : a Randomised Controlled Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"University College, London","startDate":"2019-06-18","conditions":"Stroke, Acute, Atrial Fibrillation","enrollment":3648},{"nctId":"NCT06387407","phase":"","title":"Population Pharmacokinetic Study of the Effect of Polymorphisms in the ABCB1 and CES1 Genes on the Pharmacokinetics of Dabigatran","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Hospital Of Guizhou Medical University","startDate":"2024-05-01","conditions":"Combined Analysis of Polymorphisms and Dabigatran Pharmacokinetic Parameters","enrollment":30},{"nctId":"NCT05006287","phase":"PHASE2","title":"The Safety of Non-vitamin K Oral Anticoagulants Compared to Warfarin Early After Cardiac Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Paul's Hospital, Canada","startDate":"2022-10-12","conditions":"Atrial Fibrillation","enrollment":100},{"nctId":"NCT06360055","phase":"NA","title":"Effect of Oral D-mannose Tablets on Pharmacokinetics of Dabigatranate in Healthy Adults","status":"RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2024-04-01","conditions":"Health","enrollment":12},{"nctId":"NCT05802576","phase":"","title":"Study of Interference Between Oral Anticoagulants and Heparin During Ablation of Atrial Fibrillation (AF) or Left Atrial Tachycardia (GAD) by Catheter.","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-07-08","conditions":"Atrial Fibrillation, Atrial Tachycardia","enrollment":100},{"nctId":"NCT05064800","phase":"PHASE1","title":"PF-07321332/Ritonavir and Ritonavir on Dabigatran Study in Healthy Participants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-09-21","conditions":"Healthy Participants","enrollment":24},{"nctId":"NCT06057467","phase":"NA","title":"Early Versus Late Initiation of Anticoagulation in Mild-to-moderate AIS Patients With NVAF","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-09-15","conditions":"Acute Ischemic Stroke, Atrial Fibrillation","enrollment":2351},{"nctId":"NCT06058130","phase":"NA","title":"Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-09-29","conditions":"Acute Ischemic Stroke, Atrial Fibrillation, Stenosis, Carotid","enrollment":2171},{"nctId":"NCT01613443","phase":"","title":"Ex-vivo Effect of New Oral Anticoagulants on Point-of-care Devices","status":"COMPLETED","sponsor":"Cardioangiologisches Centrum Bethanien","startDate":"2012-06","conditions":"Effect of NOAC on POCT","enrollment":100},{"nctId":"NCT05051904","phase":"","title":"A Study Based on Japanese Medical Records That Looks at Bleeding Events in People With Atrial Fibrillation and Coronary Artery Disease Who Start Taking Either Dabigatran, Rivaroxaban, or Warfarin","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2022-05-17","conditions":"Coronary Artery Disease, Atrial Fibrillation","enrollment":39357},{"nctId":"NCT04042155","phase":"","title":"Real-life Clinical Outcomes of Direct Oral Anticoagulants (MACACOD)","status":"UNKNOWN","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2019-07-29","conditions":"Atrial Fibrillation, Recurrent Venous Thromboembolism","enrollment":1600},{"nctId":"NCT04257032","phase":"PHASE1","title":"A Study in Healthy Men to Test the Influence of BI 1323495 on the Amount of the Medicines Rosuvastatin and Dabigatran in the Blood","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2020-02-13","conditions":"Healthy","enrollment":28},{"nctId":"NCT06273215","phase":"PHASE4","title":"Evaluation of the Pharmacokinetics of Microdose Midazolam, Dabigatran, Pitavastatin, Atorvastatin and Rosuvastatin in Diabetic Patients","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2023-03-05","conditions":"Diabetes","enrollment":48},{"nctId":"NCT04262492","phase":"","title":"International Registry of Thrombotic APS Patients Treated With Direct Oral Anticoagulants","status":"RECRUITING","sponsor":"Stéphane Zuily","startDate":"2020-10-21","conditions":"Antiphospholipid Syndrome, Thrombosis, Anticoagulants Causing Adverse Effects in Therapeutic Use","enrollment":500},{"nctId":"NCT04749914","phase":"PHASE1","title":"A Study of Lasmiditan in Healthy Volunteers","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2021-02-15","conditions":"Healthy","enrollment":97}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Pradaxa"],"phase":"marketed","status":"active","brandName":"Dabigatran etexilate (Pradaxa)","genericName":"Dabigatran etexilate (Pradaxa)","companyName":"Bayer","companyId":"bayer","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Dabigatran etexilate is a prodrug that converts to dabigatran, a direct thrombin inhibitor that blocks the final step of the coagulation cascade. Used for Atrial fibrillation for stroke and systemic embolism prevention, Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), Prophylaxis of DVT and PE following hip replacement surgery.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}